Newsfiscal.ai
Moleculin Biotech Announces Acceptance of Annamycin Data for Presentation at 2026 ASH Annual Meeting
· Published
Article summary
Moleculin Biotech, Inc. announced that an abstract featuring data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…